FAMILY-FOUNDED · INTERNATIONAL · EVIDENCE-LED

ASH1L, mapped across biology, body systems, and time.

A public clinical and translational research hub connecting a governed 61-person cohort with longitudinal evidence, public variant data, and testable biology—without separating a claim from its denominator, source, or uncertainty.

Current anchor61 de-identified people19 countriesevidence reviewed July 23, 2026

Conceptual scientific atlas showing chromatin surrounded by distinct cellular contexts and a time-and-recovery orbit
Conceptual research map—not a proven causal pathway. Tissue, state, and recovery links remain questions unless directly supported.
61active people
19countries represented
15clinical lanes
6molecular contexts

Roster-level architecture—not phenotype prevalence.

START HERE · WHAT IS ASH1L?

ASH1L is a dosage-sensitive chromatin-regulation gene.

Its established human disease association is neurodevelopmental. The open scientific question is how specific molecular findings change ASH1L function across cell types, developmental windows, physiological states, and time.

01 · THE GENE

ASH1 like histone lysine methyltransferase

ASH1L encodes a large, multi-domain chromatin regulator with separable recruitment, reader, catalytic, and chromatin-engagement functions.

Gene, protein & dosage →
02 · THE DISORDER

Reduced functional dosage can cause disease.

A disease-causing change in one copy can produce autosomal-dominant ASH1L-related neurodevelopmental disorder. Gene-level dosage evidence does not make every allele equivalent.

ClinGen dosage evidence ↗
03 · THE HUMAN PHENOTYPE

There is no single ASH1L presentation.

Development, communication, learning, behavior, sleep, movement, seizures, and broader multisystem findings vary across people and across age.

Genotype × phenotype × time →

ONE COHORT · FOUR EVIDENCE DEPTHS

The denominator travels with every claim.

These are nested documentation depths, not four estimates of the same thing. A detailed result from a record-rich person cannot be promoted to the 61-person denominator.

  1. 0161

    active roster

    The full person-level anchor.

  2. 0251

    phenotype-bearing profiles

    At least one mapped clinical observation.

  3. 0320

    record-backed minimum

    The strict clinical-depth subset.

  4. 0415

    deep longitudinal packets

    Age-ordered, detail-rich reconstructions.

Core reading rule

Unreported is not negative. A mapped observation is not automatically record-backed. A recurring molecular finding is not automatically an independent family event.

Evidence, denominators & privacy →

HOW THIS HUB READS ASH1L

No single view is enough.

Molecular architecture, clinical systems, chronology, and evidence class stay connected. Removing any one of them can create a stronger-looking but less valid conclusion.

  1. 01

    Molecular context

    LoF/truncating, missense, CNV/deletion, complex/mixed, splice/protein-undefined, and pending contexts are not analytically interchangeable.

    Open this layer →
  2. 02

    Clinical system

    Fifteen lanes preserve development, neurology, sleep, GI, ENT, movement, immune, autonomic, growth, medication, school, and adult function.

    Open this layer →
  3. 03

    Time & physiological state

    Age, illness, sleep, fuel state, hormones, procedures, medication, and recovery can change what is measurable.

    Open this layer →
  4. 04

    Evidence class

    Formal records, reported formal content, parent observation, controls, unresolved findings, and hypotheses remain visibly separate.

    Open this layer →

BIOLOGY WITHOUT OVERREACH

From functional dosage to cell state: established, measured, and still unproven.

The Biology page separates the human-genetic anchor from direct molecular evidence, model-system findings, and the hypotheses that require patient-allele, time-resolved, rescue-supported experiments.

E1

Established human evidence

ASH1L has a definitive autosomal-dominant neurodevelopmental gene–disease relationship, and haploinsufficiency is an established mechanism.

E2–E3

Measured experimental biology

Protein structure, chromatin biochemistry, neural-cell perturbation, and tissue models define specific functions and assays.

X

Active mechanistic questions

Allele, cell identity, developmental state, time course, and rescue must be connected before a shared mechanism can be claimed.

FOR ASH1L FAMILIES

Join the independent parent working group.

Connect with other ASH1L parents. Community participation is separate from research consent or medical-record sharing.